Log in using OpenID

Nanobodies Market Expectations and Growth Trends Highlighted Until 2026

Nanobodies are considered to be one of the best technology in the fields of research, diagnostics and therapy especially in cancer research.
Nanobodies Market Size, Outlook, Future
Analysis And Synthesis By 2026
Nanobodies are considered to be one of the best technology in the fields of research, diagnostics and
therapy especially in cancer research. These technology was developed from antigen binding fragments,
originating from Camelid heavy-chain antibodies. These molecules do not have light chains, which is an
essential part of antibody found in humans. Based on the above finding, nanobodies molecule containing
single-domain only were developed, and these molecules contain functional and structural properties
similar to heavy chain antibodies. These molecules have several advantages as compared to the
conventional antibodies such as small-size, nano to picomolar affinities, and multiple route of
administration. Ablynx, which is acquired by Sanofi S.A., is one of the leading company in this market.
Ask For Sample Copy @
Nanobodies Market Drivers
Currently, no products are available in the market, but there are multiple products in the pipeline
including few in very late stage of clinical trials. For instance, marketing authorization application for
Caplacizumab for the treatment of acquired thrombotic thrombocytopenic purpura (aTTP) has been
submitted to European Medicine Agency (EMA) in February 2017. The product, Caplacizumab, is
expected to be launched in Europe in 2018. Moreover, the company, Ablynx, is expected to file for
biologic license agreement to the U.S. Food and Drug Administration (FDA) in 2018, and is expected to
launch this product in U.S. in 2019. Both, Europe and U.S. are the key markets for any biologics
including monoclonal antibodies and are expected to be the high revenue generating market for
nanobodies. Hence, approval by regulatory bodies in Europe and U.S. to Caplacizumab in very near
future (i.e. 2018, 2019) is expected to drive the growth of global nanobodies market. As per the
company, Ablynx, estimates the product has potential to generate more than US$ 1 Bn. Furthermore,
there are multiple products in early stage of clinical development i.e. preclinical, phase 0, and phase 1.
Ablynx alone had 8 products in clinical development phase (i.e. phase 0 to phase 3) and overall 45
products in pipeline as of March 2017.
Nanobodies Market Regional Analysis
Europe is expected to hold dominant position in global nanobodies market, owing to the first
mover advantage. Marketing authorization application (MMA) to EMA for Caplacizumab was
filed by Ablynx in February 2017, and the company expects to get approval in 2018. If
approved, Europe will be the only market to have nanobodies commercially available. However,
North America is expected to show rapid growth in this market, as the company is planning to
file for biologic license agreement for the same product to U.S. FDA in 2018, and expects to
get approval from FDA by 2019.
Report includes chapters which deeply display the following deliverable about industry :
• Nanobodies Market Research Objective and Assumption
• Nanobodies Market Purview - Report Description, Executive Summary, and Coherent
Opportunity Map (COM)
• Nanobodies Market Dynamics, Regulations, and Trends Analysis - Market Dynamics,
Regulatory Scenario, Industry Trend, Merger and Acquisitions, New system Launch/Approvals,
Value Chain Analysis, Porter’s Analysis, and PEST Analysis
• Global Nanobodies Market, By Regions
• Nanobodies Market Competition by Manufacturers including Production, Share, Revenue,
Average Price, Manufacturing Base Distribution, Sales Area and Product Type.
• Nanobodies Market Manufacturers Profiles/Analysis including Company Basic Information,
Manufacturing Base and Its Competitors.
• Nanobodies Market Manufacturing Cost Analysis including Key Raw Materials and Key
Suppliers of Raw Materials.
• Industrial Chain, Sourcing Strategy and Downstream Buyers including Upstream Raw Materials
Sourcing and Downstream Buyers
• Marketing Strategy Analysis, Distributors/Traders including Marketing Channel, Market
Positioning and Distributors/Traders List.
• Market Effect Factors Analysis including Technology Progress/Risk, Consumer Needs/Customer
Preference Change and Economic/Political Environmental Change.
• Nanobodies Market Forecast including Production, Consumption, Import and Export Forecast
by Type, Applications and Region.
• Research Findings and Conclusion
Nanobodies Market Key Players
Ablynx (now part of Sanofi S. A.) is the key player in the global nanobodies market. Moreover, the
company is developing various products with leading biology companies such as
1. Novo Nordisk A/S
2. Merck & Co., Inc.
3. Merck KGaA
4. AbbVie, Inc.
5. C.H. Boehringer Sohn AG & Ko. KG.
Nanobodies Market Taxonomy:
The global nanobodies market is segmented on the basis of product type, indication, distribution
channel, and region:
By Product TypeMono-specific: Monovalent, Multivalent, Bi-paratopic
By Indication - Acquired Thrombotic Thrombocytopenic Purpura (aTTP), Respiratory Syncytial Virus
(RSV) Infection, Rheumatoid Arthritis, Systemic Lupus Erythematosus, Oncology, Immune?mediated
Inflammatory Diseases (IMID), Psoriasis, Chronic Kidney Diseases, Bone Disorders, Others
By Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
By Geography- North America, Latin America, Europe, Asia Pacific, Middle East, Africa
Browse Complete Research Report @
About Coherent Market Insights
Coherent Market Insights is a prominent market research and consulting firm offering actionready syndicated research reports, custom market analysis, consulting services, and competitive
analysis through various recommendations related to emerging market trends, technologies, and
potential absolute dollar opportunity.
Contact Us
Mr. Shah
Coherent Market Insights
1001 4th Ave, #3200
Seattle, WA 98154
Tel: +1-206-701-6702
Email: [email protected]
Poul Master
Poul Master247   documents Email
Health and Medicine
File Size
344 KB
Nanobodies Market, nanobodies
Report inappropriate content